Example: Heart Attack

Search clinical trials for: Phenobarbital

Total 81 results

    • NCT04320940
      Recruiting
      Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures
      Conditions: Epilepsy, Benign Neonatal
    • NCT03602118
      Withdrawn
      Study to Evaluate Phenobarbital Sodium Injection for the Treatment of Neonatal Seizures
      Conditions: Neonatal Seizure
    • NCT04156464
      Recruiting
      Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit
      Conditions: Alcohol Withdrawal; Alcohol Withdrawal Delirium
    • NCT03586089
      Not yet recruiting
      Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome
      Conditions: Alcohol Withdrawal Delirium; Alcohol Withdrawal; Alcohol Withdrawal Seizures
    • NCT03670160
      Suspended
      Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome
      Conditions: Neonatal Abstinence Syndrome
    • NCT01089504
      Terminated
      Prophylactic Phenobarbital After Neonatal Seizures
      Conditions: Neonatal Seizures
    • NCT01184417
      Completed
      Phenobarbital for Acute Alcohol Withdrawal
      Conditions: Alcohol Withdrawal
    • NCT03025906
      Recruiting
      Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus
      Conditions: Generalized Convulsive Status Epilepticus
    • NCT01284556
      Completed
      Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures
      Conditions: Epilepsy
    • NCT00009620
      Completed
      Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage
      Conditions: Infant, Newborn; Infant, Low Birth Weight; Infant, Small for Gestational Age; Infant, Premature; Intracranial Hemorrhages
    • NCT03788889
      Withdrawn
      Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine
      Conditions: Alcohol Withdrawal Syndrome
    • NCT01224457
      Completed
      Effect of CYP2C9/CYP2C19 Polymorphism on Pharmacokinetics of Phenobarbital in Korean Neonatal Seizure Patients.
      Conditions: Neonatal Seizure
    • NCT01720667
      Completed
      Efficacy of Intravenous Levetiracetam in Neonatal Seizures
      Conditions: Neonatal Seizures
    • NCT00530413
      Withdrawn
      Study of Phenobarbital Inhibition of Catamenial Epilepsy
      Conditions: Epilepsy
    • NCT03107507
      Unknown status
      Efficacy of Levetiracetam in Control of Neonatal Seizures Guided by an EEG
      Conditions: Neonatal Seizures
    • NCT01175668
      Terminated
      Clonidine for Neonatal Abstinence Syndrome Study
      Conditions: Neonatal Abstinence Syndrome
    • NCT03650270
      Completed
      Childhood Convulsive Status Epilepticus Management In A Resource Limited Setting
      Conditions: Pediatric Status Epilepticus
    • NCT00002759
      Completed
      Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
      Conditions: Drug/Agent Toxicity by Tissue/Organ; Lymphoma; Neutropenia; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    • NCT02550028
      Active, not recruiting
      Levetiracetam Treatment of Neonatal Seizures
      Conditions: Neonatal Seizures
    • NCT01723722
      Completed
      Treatment of Neonatal Abstinence Syndrome
      Conditions: Neonatal Abstinence Syndrome
    • NCT02810782
      Completed
      How to Treat Opiate Withdrawal in Neonates
      Conditions: Neonatal Abstinence Syndrome
    • NCT02421068
      Completed
      Population PK/PD of Off Label Drugs in Premature Neonates
      Conditions: Premature Birth
    • NCT02726867
      Withdrawn
      Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus
      Conditions: Epilepsy; Status Epilepticus
    • NCT01475656
      Terminated
      Efficacy of Keppra for Neonatal Seizures
      Conditions: Neonatal Seizures
    • NCT00381537
      Completed
      Prediction of Childhood Epilepsy Outcome in Bangladesh
      Conditions: Epilepsy
      Medical Conditions
      Sponsors and Collaborators
      Drug Interventions
      Conditions
      Rare Diseases
      Drug Interventions
      Dietary Supplements
      Sponsor/Collaborators
      Locations